<DOC>
	<DOC>NCT01170338</DOC>
	<brief_summary>Assess the role of a nicotine antagonist in helping patients presenting to hospital with acute coronary syndrome to stop smoking.</brief_summary>
	<brief_title>Safety and Efficacy of the Novel Selective Nicotinic Receptor Partial Agonist, CHANTIX (Varenicline) in Patients With Acute Coronary Syndrome</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Acute Coronary Syndrome</mesh_term>
	<mesh_term>Varenicline</mesh_term>
	<criteria>active smokers presenting to hospital with an acute coronary syndrome patients with an acute coronary syndrome who are not active smokers</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2010</verification_date>
	<keyword>smoking</keyword>
	<keyword>tobacco abuse</keyword>
</DOC>